Hypertension hot potato Print
Written by FHI's Week in Review   
Monday, 29 April 2019 16:45
 
The New England Journal of Medicine, in an April 25 post, examines the ramifications associated with the tainted valsartan, irbesartan and losartan (ARBs) that were subject to recall earlier this year. ARBs are commonly prescribed to patients suffering from hypertension as well as heart failure and kidney disease. One third of all FDA drug recalls issued since July 2018 have involved ARB-containing products, and together the recalls have affected one sixth of U.S. ARB manufacturers. As many as 2 million patients have probably been exposed to these carcinogen-contaminated ARBs manufactured in China, according to a Wall Street Journal report.
 
Read more in the current issue of Week in Review>> https://conta.cc/2ZLAPFm
 
Last Updated on Monday, 29 April 2019 16:48